{"nctId":"NCT02836236","briefTitle":"Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Treatment of Hepatitis B e Antigen-Negative Hepatitis B (China)","startDateStruct":{"date":"2015-06-19","type":"ACTUAL"},"conditions":["HBV","Chronic HBV Infection"],"count":155,"armGroups":[{"label":"Double-Blind TAF","type":"EXPERIMENTAL","interventionNames":["Drug: TAF","Drug: TDF Placebo"]},{"label":"Double-Blind TDF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TDF","Drug: TAF Placebo"]},{"label":"Open-label TAF","type":"EXPERIMENTAL","interventionNames":["Drug: TAF"]}],"interventions":[{"name":"TAF","otherNames":["GS-7340","Vemlidy®"]},{"name":"TDF","otherNames":["Viread®"]},{"name":"TAF Placebo","otherNames":[]},{"name":"TDF Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures\n* Adult males and non-pregnant, non-lactating females\n* Documented evidence of chronic HBV infection\n* Hepatitis e antigen (HBeAg)-negative, chronic hepatitis B with all of the following:\n\n  * HBeAg-negative and hepatitis B e antibody (HBeAb) positive at screening\n  * Screening HBV DNA ≥ 2 x 10\\^4 IU/mL\n  * Screening serum alanine aminotransferase (ALT) level \\> 60 U/L (males) or \\> 38 U/L (females) and ≤ 10 x the upper limit of the normal range (ULN)\n* Treatment-naive participants (defined as \\< 12 weeks of oral antiviral treatment with any nucleoside or nucleotide analogue), OR treatment-experienced participants (defined as participants meeting all entry criteria \\[including HBV DNA and serum ALT criteria\\] and with ≥ 12 weeks of previous treatment with any nucleoside or nucleotide analogue)\n* Previous treatment with interferon (pegylated or non-pegylated) must have ended at least 6 months prior to the baseline visit.\n* Adequate renal function\n* Normal ECG\n\nKey Exclusion Criteria:\n\n* Females who are breastfeeding\n* Males and females of reproductive potential who are unwilling to use an \"effective\", protocol-specified method(s) of contraception during the study\n* Co-infection with hepatitis C virus, HIV, or hepatitis D virus\n* Evidence of hepatocellular carcinoma\n* Any history of, or current evidence of, clinical hepatic decompensation\n* Abnormal hematological and biochemical parameters, including aspartate aminotransferase (AST) \\> 10 x ULN\n* Received solid organ or bone marrow transplant\n* History of malignancy within the past 5 years, with the exception of specific cancers that are cured by surgical resection; individuals under evaluation for possible malignancy are not eligible\n* Currently receiving therapy with immunomodulators (eg, corticosteroids), investigational agents, nephrotoxic agents, or agents capable of modifying renal excretion\n* Individuals receiving ongoing therapy with drugs not to be used with tenofovir alafenamide or tenofovir disoproxil fumarate or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients\n* Current alcohol or substance abuse judged by the investigator to potentially interfere with participant compliance\n* Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with dosing requirements\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Hepatitis B Virus (HBV) DNA < 29 IU/mL at Week 48","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.4","spread":null},{"groupId":"OG001","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.718","spread":"2.0131"},{"groupId":"OG001","value":"-1.096","spread":"2.9200"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Spine BMD at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.740","spread":"3.3764"},{"groupId":"OG001","value":"-3.456","spread":"3.1071"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Creatinine at Week 48","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.012","spread":"0.0827"},{"groupId":"OG001","value":"0.030","spread":"0.0754"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants With Treatment-emergent Proteinuria by Urinalysis (Dipstick) Through Week 48","description":"Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":null},{"groupId":"OG001","value":"18.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"4.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":104},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Covid-19","Hepatic steatosis","Hyperlipidaemia"]}}}